ArticleCureus2025
Evaluation of Pharmacotherapeutic Patterns in Patients With Renal Impairment Undergoing Hemodialysis: A Drug Utilization Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Chronic kidney disease (CKD) and acute kidney injury (AKI) are significant contributors to renal morbidity and mortality worldwide. In India, the rising prevalence of hypertension and diabetes has led to an increase in CKD cases, with limited access to renal replacement therapies. Hemodialysis remains a common treatment modality, but patients face challenges, including complex medication regimens and adverse drug reactions. Drug Utilization Studies (DUS) are essential to evaluate prescribing patterns and promote rational drug use in this population. Methodology A cross-sectional observational study was conducted over 12 months at two setups in Surat, Gujarat, India. Ethical approval was obtained from the HREC. Adult patients (≥18 years) undergoing hemodialysis were enrolled after informed consent. Data were collected using a pre-designed case record form based on WHO core prescribing indicators. Statistical analysis was performed using IBM Corp. Released 2014. IBM SPSS Statistics for Windows, Version 20. Armonk, NY: IBM Corp. Result The study was conducted on 150 hemodialysis patients (64% male; mean age 46.5 ± 14.7 years). Most (116; 77.3%) received dialysis 2-3 times per week. Hypertension (97; 64.6%) and diabetes (37; 24.6%) were the leading comorbidities, while 35 (23%) were unaware of their illness. Parenteral medications were prescribed to 104 patients (69.3%), with erythropoietin being the most common (75; 50%). A total of 1130 drugs were prescribed, averaging 7.53 per patient. Out of the total drugs used, 680 (60.17%) were prescribed generically, and 777 (68.76%) were from the National List of Essential Medicines (NLEM). Among drug classes, cardiovascular agents were most frequent (337; 29.8%), followed by gastrointestinal (226; 20%) and hematopoietic agents (112; 12%). Significant differences in drug usage were observed between healthcare setups (p < 0.01). Conclusion The study reveals a high prevalence of hypertension and polypharmacy among hemodialysis patients, with significant reliance on cardiovascular and gastrointestinal drugs. Generic and essential drug prescribing rates were suboptimal, and injection use was notably high. Statistically significant differences in drug utilization patterns across healthcare setups underscore the need for rational prescribing and standardization of dialysis pharmacotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.